Share your contact details to receive free updated sample copy/pages of the recently published edition of Opioid Induced Constipation Drugs Market Report 2023.
Key Insights from Opioid Induced Constipation Drugs Market Report
As per Cognitive Market Research's latest published report, the Global Opioid Induced Constipation Drugs market size was USD 1.12 Billion in 2022 and it is forecasted to reach USD 1.75 Billion by 2030. Opioid Induced Constipation Drugs Industry's Compound Annual Growth Rate will be 4.57% from 2023 to 2030.
| Global Opioid Induced Constipation Drugs Market Compound Annual Growth Rate (CAGR) for 2023 to 2030 | 4.57% |
Opioid Induced Constipation Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Opioid Induced Constipation Drugs Market Report Description
What are Opioid Induced Constipation Drugs?
Opioid-induced constipation is caused by opioids, which stimulate enteric -receptors, rising tonic non-propulsive reductions in the large and small intestines, causing desiccation of stool and increasing colonic fluid absorption. The opioid-induced constipation drugs refer to several treatments and drugs, which are used to manage constipation caused by opioid use. In addition, these drugs are available and approved including chloride channel-2 activators, drugs showing surfactant effects, and mu-opioid receptor antagonists.
Factors Impacting Opioid Induced Constipation Drugs Market
Increasing demand for opioid-induced constipation drug management of opioid-induced constipation disorder and treatment is the key factor expected to drive the growth of the opioid-induced constipation drugs market. In addition, increasing awareness about the use of chloride channel type-2 activators and mu-opioid receptor antagonists are expected to drive the growth of the opioid-induced constipation drugs market.
Opioid-Induced Constipation Drugs Market Opportunities:
Increasing research and development activities, regulatory approvals, demand for therapeutics for treating opioid-induced constipation, and spending for opioid-induced constipation research create growth opportunities for the opioid-induced constipation drugs market in the forecast period.
Opioid-Induced Constipation Drugs Market Restraints:
The increasing cost of pharmaceuticals and side effects of using opioid-induced constipation drugs anticipated to hamper the growth of the opioid-induced constipation drugs market.
| Base Year | 2022 |
| Historical Data Time Period | 2018-2022 |
| Forecast Period | 2023-2030 |
| Report Edition | 7th Edition (2023) |
| Last Update | Last Updated In April 2023 |
| Next Report Edition | June 2023 (Pre-Booking Available) |
| Market Forecast/Projection Time Period | 2023-2030 |
| Report Format | PDF | PPT | Excel | Word | Bi |
| Report ID | CMR890183 |
Opioid Induced Constipation Drugs Market Report 2023 (Global Edition) Table of Content differs according to the user License selection. Current Displayed TOC is for the Single User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report. Specific section/s of report can be ordered at a discounted price. If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Table of Content (Revenue USD Edition), (Enquire about Volume/Consumption Edition Data)
- 1.1 Global Opioid Induced Constipation Drugs Industry Introduction
- 1.2 Objectives of the Study
- 1.3 USP of the Report
- 1.4 Who is this report for?
- 1.5 Designing of Market Scope
- 1.5.1 Opioid Induced Constipation Drugs Market Segmentation
- 1.5.1 Opioid Induced Constipation Drugs Market Regional Fragmentation
- 1.5.1 Opioid Induced Constipation Drugs Market Players
- 1.6 Report Duration
- 1.7 List of Stakeholders
- 2.1 Opioid Induced Constipation Drugs Market Report 2023 Research Methodology
- 2.2 Systematic Research Approach
- 2.2.1 Primary Research
- 2.2.1.1 Key Data from Primary
- 2.2.1.2 Primary Interviews with Experts
- 2.2.1.3 Key Industry Insights
- 2.2.1.4 Questionnaire
At Cognitive Market Research, we have designed questionnaire focused on Opioid Induced Constipation Drugs Market for the statistical study. This questionnaire is the key part of our research methodology which is shared with number of Opioid Induced Constipation Drugs industry experts of entire value chain, located across the globe. This study help us to gather accurate quantitative and qualitative data for the final report.
- 2.2.1.5 Breakdown of Primaries
- 2.2.2 Secondary Research
- 2.2.2.1 Key Data from Secondary
- 2.2.2.2 Paid Sources
- 2.2.2.3 Public Sources
- 2.2.1 Primary Research
- 2.3 Market Size Estimation
- 2.3.1 Top-Down Approach
- 2.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 2.3.1 Bottom-UP Approach
- 2.3.1.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 2.3.1 Top-Down Approach
- 2.4 Market Breakdown and Data Triangulation
- 2.5 Research Assumptions
- 3.1 Global Opioid Induced Constipation Drugs Market Size 2018 – 2030, (USD Million)
- 3.2 Global Opioid Induced Constipation Drugs Value, Absolute & Opportunity Analysis
- 3.3 Global Opioid Induced Constipation Drugs Market Y-o-Y Growth Rate Projection by Region (2023 - 2030)
- 3.4 Global Opioid Induced Constipation Drugs Market Statistics 2022: Snapshot
- 4.1 Opioid Induced Constipation Drugs Introduction
- 4.2 Global Opioid Induced Constipation Drugs Market Statistics by Regions (2018-2030)
- 4.2.1 North America Opioid Induced Constipation Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.2 Europe Opioid Induced Constipation Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.3 Asia Pacific Opioid Induced Constipation Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.4 Latin America Opioid Induced Constipation Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.5 Middle East and Africa Opioid Induced Constipation Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.3 Global Opioid Induced Constipation Drugs Market Size (2018-2030)
- 4.3.1 Global Opioid Induced Constipation Drugs Revenue Status and Outlook (2018-2030)
- 4.4 Global Opioid Induced Constipation Drugs Market Price Analysis by Regions (2018-2030)
- 5.1 Global Opioid Induced Constipation Drugs Market Revenue and Share by Manufacturers (2018-2022)
- 5.2 Global Opioid Induced Constipation Drugs Industry Mergers and Acquisition Analysis
- 5.3 Global Opioid Induced Constipation Drugs New Launches Analysis
- 5.4 Company Categorization
- 5.5 Global Opioid Induced Constipation Drugs Top Winning Strategies, by Manufacturers (2018-2022)
- 7.1 Opioid Induced Constipation Drugs Industrial Dynamics
- 7.1.1 Global Opioid Induced Constipation Drugs Market Drivers
- 7.1.2 Global Opioid Induced Constipation Drugs Market Restrains
- 7.1.3 Global Opioid Induced Constipation Drugs Market Opportunities
- 7.1.4 Global Opioid Induced Constipation Drugs Market Trends
- 7.1.5 Global Opioid Induced Constipation Drugs Technology (Road Map)
- 7.2 Opioid Induced Constipation Drugs Market Attractiveness Analysis
- 7.1.1 Market Attractiveness Analysis by Type Segment
- 7.1.2 Market Attractiveness Analysis by Application Segment
- 7.3 PESTEL Analysis for Opioid Induced Constipation Drugs Market
- 7.3.1 Political Factors
- 7.3.2 Economic Factors
- 7.3.3 Social Factors
- 7.3.4 Technological Factors
- 7.3.5 Legal Factors
- 7.3.6 Environmental Factors
- 7.4 Porter’s Five Forces Analysis for Opioid Induced Constipation Drugs Market
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of Substitutes
- 7.4.4 Threat of New Entrants
- 7.4.5 Degree of Competition
- 7.5 of Opioid Induced Constipation Drugs Market Product Life Cycle
- 7.6 COVID-19 Impact on Opioid Induced Constipation Drugs Industry
- 7.4.1 Overall Impact of COVID-19 on Opioid Induced Constipation Drugs Industry
- 7.4.2 Post COVID-19 Impact and Recovery Analysis
- 7.4.3 Influencing Factors
- 7.7 Consumer Preference Analysis for Opioid Induced Constipation Drugs Market
- 7.8 Patent Analysis of Opioid Induced Constipation Drugs
- 7.9 Opioid Induced Constipation Drugs Industrial Chain Analysis
- 7.10 Manufacturing Cost Analysis
- 7.11 Supply Side Analysis
- 8.1 Ironwood Pharmaceuticals Inc
- 8.1.1 Ironwood Pharmaceuticals Inc Company Basic Information, and Sales Area
- 8.1.2 Ironwood Pharmaceuticals Inc Business Segment/ Overview
- 8.1.3 Ironwood Pharmaceuticals Inc Financials
- 8.1.3.1 Investment in Research and Development
- 8.1.3.2 Ironwood Pharmaceuticals Inc Sales Revenue (2018-2022)
- 8.1.3.3 Ironwood Pharmaceuticals Inc Market Share (2018-2022)
- 8.1.4 Ironwood Pharmaceuticals Inc Recent Developments
- 8.1.5 Ironwood Pharmaceuticals Inc Business Strategy
- 8.1.6 Ironwood Pharmaceuticals Inc Management Change
- 8.1.7 Ironwood Pharmaceuticals Inc SWOT Analysis
- 8.1.7.1 Strength
- 8.1.7.2 Weakness
- 8.1.7.3 Opportunity
- 8.1.7.4 Threats
- 8.1.8 Ironwood Pharmaceuticals Inc COVID-19 Impact Analysis
- 8.2 Daiichi Sankyo Co Ltd
- 8.2.1 Daiichi Sankyo Co Ltd Company Basic Information, and Sales Area
- 8.2.2 Daiichi Sankyo Co Ltd Business Segment/ Overview
- 8.2.3 Daiichi Sankyo Co Ltd Financials
- 8.2.3.1 Investment in Research and Development
- 8.2.3.2 Daiichi Sankyo Co Ltd Sales Revenue (2018-2022)
- 8.2.3.3 Daiichi Sankyo Co Ltd Market Share (2018-2022)
- 8.2.4 Daiichi Sankyo Co Ltd Recent Developments
- 8.2.5 Daiichi Sankyo Co Ltd Business Strategy
- 8.2.6 Daiichi Sankyo Co Ltd Management Change
- 8.2.7 Daiichi Sankyo Co Ltd SWOT Analysis
- 8.2.7.1 Strength
- 8.2.7.2 Weakness
- 8.2.7.3 Opportunity
- 8.2.7.4 Threats
- 8.2.8 Daiichi Sankyo Co Ltd COVID-19 Impact Analysis
- 8.3 Pfizer
- 8.3.1 Pfizer Company Basic Information, and Sales Area
- 8.3.2 Pfizer Business Segment/ Overview
- 8.3.3 Pfizer Financials
- 8.3.3.1 Investment in Research and Development
- 8.3.3.2 Pfizer Sales Revenue (2018-2022)
- 8.3.3.3 Pfizer Market Share (2018-2022)
- 8.3.4 Pfizer Recent Developments
- 8.3.5 Pfizer Business Strategy
- 8.3.6 Pfizer Management Change
- 8.3.7 Pfizer SWOT Analysis
- 8.3.7.1 Strength
- 8.3.7.2 Weakness
- 8.3.7.3 Opportunity
- 8.3.7.4 Threats
- 8.3.8 Pfizer COVID-19 Impact Analysis
- 8.4 Progenics Pharmaceuticals Inc
- 8.4.1 Progenics Pharmaceuticals Inc Company Basic Information, and Sales Area
- 8.4.2 Progenics Pharmaceuticals Inc Business Segment/ Overview
- 8.4.3 Progenics Pharmaceuticals Inc Financials
- 8.4.3.1 Investment in Research and Development
- 8.4.3.2 Progenics Pharmaceuticals Inc Sales Revenue (2018-2022)
- 8.4.3.3 Progenics Pharmaceuticals Inc Market Share (2018-2022)
- 8.4.4 Progenics Pharmaceuticals Inc Recent Developments
- 8.4.5 Progenics Pharmaceuticals Inc Business Strategy
- 8.4.6 Progenics Pharmaceuticals Inc Management Change
- 8.4.7 Progenics Pharmaceuticals Inc SWOT Analysis
- 8.4.7.1 Strength
- 8.4.7.2 Weakness
- 8.4.7.3 Opportunity
- 8.4.7.4 Threats
- 8.4.8 Progenics Pharmaceuticals Inc COVID-19 Impact Analysis
- 8.5 Shionogi Co. Ltd
- 8.5.1 Shionogi Co. Ltd Company Basic Information, and Sales Area
- 8.5.2 Shionogi Co. Ltd Business Segment/ Overview
- 8.5.3 Shionogi Co. Ltd Financials
- 8.5.3.1 Investment in Research and Development
- 8.5.3.2 Shionogi Co. Ltd Sales Revenue (2018-2022)
- 8.5.3.3 Shionogi Co. Ltd Market Share (2018-2022)
- 8.5.4 Shionogi Co. Ltd Recent Developments
- 8.5.5 Shionogi Co. Ltd Business Strategy
- 8.5.6 Shionogi Co. Ltd Management Change
- 8.5.7 Shionogi Co. Ltd SWOT Analysis
- 8.5.7.1 Strength
- 8.5.7.2 Weakness
- 8.5.7.3 Opportunity
- 8.5.7.4 Threats
- 8.5.8 Shionogi Co. Ltd COVID-19 Impact Analysis
- 8.6 Allergan Plc
- 8.6.1 Allergan Plc Company Basic Information, and Sales Area
- 8.6.2 Allergan Plc Business Segment/ Overview
- 8.6.3 Allergan Plc Financials
- 8.6.3.1 Investment in Research and Development
- 8.6.3.2 Allergan Plc Sales Revenue (2018-2022)
- 8.6.3.3 Allergan Plc Market Share (2018-2022)
- 8.6.4 Allergan Plc Recent Developments
- 8.6.5 Allergan Plc Business Strategy
- 8.6.6 Allergan Plc Management Change
- 8.6.7 Allergan Plc SWOT Analysis
- 8.6.7.1 Strength
- 8.6.7.2 Weakness
- 8.6.7.3 Opportunity
- 8.6.7.4 Threats
- 8.6.8 Allergan Plc COVID-19 Impact Analysis
- 8.7 Nektar Therapeutics
- 8.7.1 Nektar Therapeutics Company Basic Information, and Sales Area
- 8.7.2 Nektar Therapeutics Business Segment/ Overview
- 8.7.3 Nektar Therapeutics Financials
- 8.7.3.1 Investment in Research and Development
- 8.7.3.2 Nektar Therapeutics Sales Revenue (2018-2022)
- 8.7.3.3 Nektar Therapeutics Market Share (2018-2022)
- 8.7.4 Nektar Therapeutics Recent Developments
- 8.7.5 Nektar Therapeutics Business Strategy
- 8.7.6 Nektar Therapeutics Management Change
- 8.7.7 Nektar Therapeutics SWOT Analysis
- 8.7.7.1 Strength
- 8.7.7.2 Weakness
- 8.7.7.3 Opportunity
- 8.7.7.4 Threats
- 8.7.8 Nektar Therapeutics COVID-19 Impact Analysis
- 8.8 Purdue Pharma
- 8.8.1 Purdue Pharma Company Basic Information, and Sales Area
- 8.8.2 Purdue Pharma Business Segment/ Overview
- 8.8.3 Purdue Pharma Financials
- 8.8.3.1 Investment in Research and Development
- 8.8.3.2 Purdue Pharma Sales Revenue (2018-2022)
- 8.8.3.3 Purdue Pharma Market Share (2018-2022)
- 8.8.4 Purdue Pharma Recent Developments
- 8.8.5 Purdue Pharma Business Strategy
- 8.8.6 Purdue Pharma Management Change
- 8.8.7 Purdue Pharma SWOT Analysis
- 8.8.7.1 Strength
- 8.8.7.2 Weakness
- 8.8.7.3 Opportunity
- 8.8.7.4 Threats
- 8.8.8 Purdue Pharma COVID-19 Impact Analysis
- 8.9 S.L.A. Pharma AG
- 8.9.1 S.L.A. Pharma AG Company Basic Information, and Sales Area
- 8.9.2 S.L.A. Pharma AG Business Segment/ Overview
- 8.9.3 S.L.A. Pharma AG Financials
- 8.9.3.1 Investment in Research and Development
- 8.9.3.2 S.L.A. Pharma AG Sales Revenue (2018-2022)
- 8.9.3.3 S.L.A. Pharma AG Market Share (2018-2022)
- 8.9.4 S.L.A. Pharma AG Recent Developments
- 8.9.5 S.L.A. Pharma AG Business Strategy
- 8.9.6 S.L.A. Pharma AG Management Change
- 8.9.7 S.L.A. Pharma AG SWOT Analysis
- 8.9.7.1 Strength
- 8.9.7.2 Weakness
- 8.9.7.3 Opportunity
- 8.9.7.4 Threats
- 8.9.8 S.L.A. Pharma AG COVID-19 Impact Analysis
- 8.10 Mundipharma International Limited
- 8.10.1 Mundipharma International Limited Company Basic Information, and Sales Area
- 8.10.2 Mundipharma International Limited Business Segment/ Overview
- 8.10.3 Mundipharma International Limited Financials
- 8.10.3.1 Investment in Research and Development
- 8.10.3.2 Mundipharma International Limited Sales Revenue (2018-2022)
- 8.10.3.3 Mundipharma International Limited Market Share (2018-2022)
- 8.10.4 Mundipharma International Limited Recent Developments
- 8.10.5 Mundipharma International Limited Business Strategy
- 8.10.6 Mundipharma International Limited Management Change
- 8.10.7 Mundipharma International Limited SWOT Analysis
- 8.10.7.1 Strength
- 8.10.7.2 Weakness
- 8.10.7.3 Opportunity
- 8.10.7.4 Threats
- 8.10.8 Mundipharma International Limited COVID-19 Impact Analysis
- 8.11 Ono Pharmaceutical Co. Ltd
- 8.11.1 Ono Pharmaceutical Co. Ltd Company Basic Information, and Sales Area
- 8.11.2 Ono Pharmaceutical Co. Ltd Business Segment/ Overview
- 8.11.3 Ono Pharmaceutical Co. Ltd Financials
- 8.11.3.1 Investment in Research and Development
- 8.11.3.2 Ono Pharmaceutical Co. Ltd Sales Revenue (2018-2022)
- 8.11.3.3 Ono Pharmaceutical Co. Ltd Market Share (2018-2022)
- 8.11.4 Ono Pharmaceutical Co. Ltd Recent Developments
- 8.11.5 Ono Pharmaceutical Co. Ltd Business Strategy
- 8.11.6 Ono Pharmaceutical Co. Ltd Management Change
- 8.11.7 Ono Pharmaceutical Co. Ltd SWOT Analysis
- 8.11.7.1 Strength
- 8.11.7.2 Weakness
- 8.11.7.3 Opportunity
- 8.11.7.4 Threats
- 8.11.8 Ono Pharmaceutical Co. Ltd COVID-19 Impact Analysis
- 8.12 Takeda Pharmaceutical Company Limited
- 8.12.1 Takeda Pharmaceutical Company Limited Company Basic Information, and Sales Area
- 8.12.2 Takeda Pharmaceutical Company Limited Business Segment/ Overview
- 8.12.3 Takeda Pharmaceutical Company Limited Financials
- 8.12.3.1 Investment in Research and Development
- 8.12.3.2 Takeda Pharmaceutical Company Limited Sales Revenue (2018-2022)
- 8.12.3.3 Takeda Pharmaceutical Company Limited Market Share (2018-2022)
- 8.12.4 Takeda Pharmaceutical Company Limited Recent Developments
- 8.12.5 Takeda Pharmaceutical Company Limited Business Strategy
- 8.12.6 Takeda Pharmaceutical Company Limited Management Change
- 8.12.7 Takeda Pharmaceutical Company Limited SWOT Analysis
- 8.12.7.1 Strength
- 8.12.7.2 Weakness
- 8.12.7.3 Opportunity
- 8.12.7.4 Threats
- 8.12.8 Takeda Pharmaceutical Company Limited COVID-19 Impact Analysis
- 8.13 Theravance Biopharma Inc
- 8.13.1 Theravance Biopharma Inc Company Basic Information, and Sales Area
- 8.13.2 Theravance Biopharma Inc Business Segment/ Overview
- 8.13.3 Theravance Biopharma Inc Financials
- 8.13.3.1 Investment in Research and Development
- 8.13.3.2 Theravance Biopharma Inc Sales Revenue (2018-2022)
- 8.13.3.3 Theravance Biopharma Inc Market Share (2018-2022)
- 8.13.4 Theravance Biopharma Inc Recent Developments
- 8.13.5 Theravance Biopharma Inc Business Strategy
- 8.13.6 Theravance Biopharma Inc Management Change
- 8.13.7 Theravance Biopharma Inc SWOT Analysis
- 8.13.7.1 Strength
- 8.13.7.2 Weakness
- 8.13.7.3 Opportunity
- 8.13.7.4 Threats
- 8.13.8 Theravance Biopharma Inc COVID-19 Impact Analysis
- 8.14 Valeant Pharmaceuticals International
- 8.14.1 Valeant Pharmaceuticals International Company Basic Information, and Sales Area
- 8.14.2 Valeant Pharmaceuticals International Business Segment/ Overview
- 8.14.3 Valeant Pharmaceuticals International Financials
- 8.14.3.1 Investment in Research and Development
- 8.14.3.2 Valeant Pharmaceuticals International Sales Revenue (2018-2022)
- 8.14.3.3 Valeant Pharmaceuticals International Market Share (2018-2022)
- 8.14.4 Valeant Pharmaceuticals International Recent Developments
- 8.14.5 Valeant Pharmaceuticals International Business Strategy
- 8.14.6 Valeant Pharmaceuticals International Management Change
- 8.14.7 Valeant Pharmaceuticals International SWOT Analysis
- 8.14.7.1 Strength
- 8.14.7.2 Weakness
- 8.14.7.3 Opportunity
- 8.14.7.4 Threats
- 8.14.8 Valeant Pharmaceuticals International COVID-19 Impact Analysis
- 8.15 Cosmo Pharmaceuticals SA
- 8.15.1 Cosmo Pharmaceuticals SA Company Basic Information, and Sales Area
- 8.15.2 Cosmo Pharmaceuticals SA Business Segment/ Overview
- 8.15.3 Cosmo Pharmaceuticals SA Financials
- 8.15.3.1 Investment in Research and Development
- 8.15.3.2 Cosmo Pharmaceuticals SA Sales Revenue (2018-2022)
- 8.15.3.3 Cosmo Pharmaceuticals SA Market Share (2018-2022)
- 8.15.4 Cosmo Pharmaceuticals SA Recent Developments
- 8.15.5 Cosmo Pharmaceuticals SA Business Strategy
- 8.15.6 Cosmo Pharmaceuticals SA Management Change
- 8.15.7 Cosmo Pharmaceuticals SA SWOT Analysis
- 8.15.7.1 Strength
- 8.15.7.2 Weakness
- 8.15.7.3 Opportunity
- 8.15.7.4 Threats
- 8.15.8 Cosmo Pharmaceuticals SA COVID-19 Impact Analysis
- 8.16 Daewoong Pharmaceutical
- 8.16.1 Daewoong Pharmaceutical Company Basic Information, and Sales Area
- 8.16.2 Daewoong Pharmaceutical Business Segment/ Overview
- 8.16.3 Daewoong Pharmaceutical Financials
- 8.16.3.1 Investment in Research and Development
- 8.16.3.2 Daewoong Pharmaceutical Sales Revenue (2018-2022)
- 8.16.3.3 Daewoong Pharmaceutical Market Share (2018-2022)
- 8.16.4 Daewoong Pharmaceutical Recent Developments
- 8.16.5 Daewoong Pharmaceutical Business Strategy
- 8.16.6 Daewoong Pharmaceutical Management Change
- 8.16.7 Daewoong Pharmaceutical SWOT Analysis
- 8.16.7.1 Strength
- 8.16.7.2 Weakness
- 8.16.7.3 Opportunity
- 8.16.7.4 Threats
- 8.16.8 Daewoong Pharmaceutical COVID-19 Impact Analysis
- 8.17 C.B. Fleet Company
- 8.17.1 C.B. Fleet Company Company Basic Information, and Sales Area
- 8.17.2 C.B. Fleet Company Business Segment/ Overview
- 8.17.3 C.B. Fleet Company Financials
- 8.17.3.1 Investment in Research and Development
- 8.17.3.2 C.B. Fleet Company Sales Revenue (2018-2022)
- 8.17.3.3 C.B. Fleet Company Market Share (2018-2022)
- 8.17.4 C.B. Fleet Company Recent Developments
- 8.17.5 C.B. Fleet Company Business Strategy
- 8.17.6 C.B. Fleet Company Management Change
- 8.17.7 C.B. Fleet Company SWOT Analysis
- 8.17.7.1 Strength
- 8.17.7.2 Weakness
- 8.17.7.3 Opportunity
- 8.17.7.4 Threats
- 8.17.8 C.B. Fleet Company COVID-19 Impact Analysis
- 8.18 Sucampo Pharmaceuticals
- 8.18.1 Sucampo Pharmaceuticals Company Basic Information, and Sales Area
- 8.18.2 Sucampo Pharmaceuticals Business Segment/ Overview
- 8.18.3 Sucampo Pharmaceuticals Financials
- 8.18.3.1 Investment in Research and Development
- 8.18.3.2 Sucampo Pharmaceuticals Sales Revenue (2018-2022)
- 8.18.3.3 Sucampo Pharmaceuticals Market Share (2018-2022)
- 8.18.4 Sucampo Pharmaceuticals Recent Developments
- 8.18.5 Sucampo Pharmaceuticals Business Strategy
- 8.18.6 Sucampo Pharmaceuticals Management Change
- 8.18.7 Sucampo Pharmaceuticals SWOT Analysis
- 8.18.7.1 Strength
- 8.18.7.2 Weakness
- 8.18.7.3 Opportunity
- 8.18.7.4 Threats
- 8.18.8 Sucampo Pharmaceuticals COVID-19 Impact Analysis
- 9.1 Detailed Qualitative Analysis
- 9.2 Global Opioid Induced Constipation Drugs Revenue and Share (%) by Drug Type (2018-2030)
- 9.2.1 Lubiprostone Market Size
- 9.2.1.1 Global Lubiprostone Market Share and Revenue (USD Million) for 2018-2030
- 9.2.1.2 Opioid Induced Constipation Drugs Market for Lubiprostone, by Country (2021 Vs 2024)
- 9.2.2 Methyl Naltrexone Bromide Market Size
- 9.2.2.1 Global Methyl Naltrexone Bromide Market Share and Revenue (USD Million) for 2018-2030
- 9.2.2.2 Opioid Induced Constipation Drugs Market for Methyl Naltrexone Bromide, by Country (2021 Vs 2024)
- 9.2.3 Naldemedine Market Size
- 9.2.3.1 Global Naldemedine Market Share and Revenue (USD Million) for 2018-2030
- 9.2.3.2 Opioid Induced Constipation Drugs Market for Naldemedine, by Country (2021 Vs 2024)
- 9.2.4 Alvimopan Market Size
- 9.2.4.1 Global Alvimopan Market Share and Revenue (USD Million) for 2018-2030
- 9.2.4.2 Opioid Induced Constipation Drugs Market for Alvimopan, by Country (2021 Vs 2024)
- 9.2.5 Chloride Channel-2 Activators Market Size
- 9.2.5.1 Global Chloride Channel-2 Activators Market Share and Revenue (USD Million) for 2018-2030
- 9.2.5.2 Opioid Induced Constipation Drugs Market for Chloride Channel-2 Activators, by Country (2021 Vs 2024)
- 9.2.6 Mu-opioid Receptor Antagonists Market Size
- 9.2.6.1 Global Mu-opioid Receptor Antagonists Market Share and Revenue (USD Million) for 2018-2030
- 9.2.6.2 Opioid Induced Constipation Drugs Market for Mu-opioid Receptor Antagonists, by Country (2021 Vs 2024)
- 9.2.7 Other Market Size
- 9.2.7.1 Global Other Market Share and Revenue (USD Million) for 2018-2030
- 9.2.7.2 Opioid Induced Constipation Drugs Market for Other, by Country (2021 Vs 2024)
- 9.2.1 Lubiprostone Market Size
- 10.1 Detailed Qualitative Analysis
- 10.2 Global Opioid Induced Constipation Drugs Revenue and Share (%) by Distribution Channel (2018-2030)
- 10.2.1 Hospital Pharmacies Market Size
- 10.2.1.1 Global Hospital Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 10.2.1.2 Opioid Induced Constipation Drugs Market for Hospital Pharmacies, by Country (2021 Vs 2024)
- 10.2.2 Drug Store and Retail Pharmacies Market Size
- 10.2.2.1 Global Drug Store and Retail Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 10.2.2.2 Opioid Induced Constipation Drugs Market for Drug Store and Retail Pharmacies, by Country (2021 Vs 2024)
- 10.2.3 Online Pharmacies Market Size
- 10.2.3.1 Global Online Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 10.2.3.2 Opioid Induced Constipation Drugs Market for Online Pharmacies, by Country (2021 Vs 2024)
- 10.2.1 Hospital Pharmacies Market Size
- 11.1 Detailed Qualitative Analysis
- 11.2 Global Opioid Induced Constipation Drugs Revenue and Share (%) by Prescription Type (2018-2030)
- 11.2.1 Prescribed Drugs Market Size
- 11.2.1.1 Global Prescribed Drugs Market Share and Revenue (USD Million) for 2018-2030
- 11.2.1.2 Opioid Induced Constipation Drugs Market for Prescribed Drugs, by Country (2021 Vs 2024)
- 11.2.2 Over The Counter Drugs Market Size
- 11.2.2.1 Global Over The Counter Drugs Market Share and Revenue (USD Million) for 2018-2030
- 11.2.2.2 Opioid Induced Constipation Drugs Market for Over The Counter Drugs, by Country (2021 Vs 2024)
- 11.2.1 Prescribed Drugs Market Size
- 12.1 Detailed Qualitative Analysis
- 12.2 Global Opioid Induced Constipation Drugs Market Revenue by Region (2018-2030)
- 12.2 Global Opioid Induced Constipation Drugs Market Share (%) by Region (2018-2030)
- 13.1 North America
- 13.1.1 North America Opioid Induced Constipation Drugs Market Trends and Analysis
- 13.1.2 North America Opioid Induced Constipation Drugs Market by Country, 2018-2030
- 13.1.3 North America Opioid Induced Constipation Drugs Market Attractiveness Analysis by Country
- 13.2 North America Opioid Induced Constipation Drugs Market Size (2018-2030)
- 13.2.1 North America Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 13.2.1.1 Lubiprostone
- 13.2.1.1.1 North America Lubiprostone Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.2 Methyl Naltrexone Bromide
- 13.2.1.2.1 North America Methyl Naltrexone Bromide Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.3 Naldemedine
- 13.2.1.3.1 North America Naldemedine Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.4 Alvimopan
- 13.2.1.4.1 North America Alvimopan Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.5 Chloride Channel-2 Activators
- 13.2.1.5.1 North America Chloride Channel-2 Activators Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.6 Mu-opioid Receptor Antagonists
- 13.2.1.6.1 North America Mu-opioid Receptor Antagonists Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.7 Other
- 13.2.1.7.1 North America Other Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.1 Lubiprostone
- 13.2.2 North America Opioid Induced Constipation Drugs Market (USD Million) by Distribution Channel (2018-2030)
- 13.2.2.1 Hospital Pharmacies
- 13.2.2.1.1 North America Hospital Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.2 Drug Store and Retail Pharmacies
- 13.2.2.2.1 North America Drug Store and Retail Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.3 Online Pharmacies
- 13.2.2.3.1 North America Online Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.1 Hospital Pharmacies
- 13.2.3 North America Opioid Induced Constipation Drugs Market (USD Million) by Prescription Type (2018-2030)
- 13.2.3.1 Prescribed Drugs
- 13.2.3.1.1 North America Prescribed Drugs Market Share and Revenue (USD Million) for 2018-2030
- 13.2.3.2 Over The Counter Drugs
- 13.2.3.2.1 North America Over The Counter Drugs Market Share and Revenue (USD Million) for 2018-2030
- 13.2.3.1 Prescribed Drugs
- 13.2.1 North America Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.1 Europe
- 14.1.1 Europe Opioid Induced Constipation Drugs Market Trends and Analysis
- 14.1.2 Europe Opioid Induced Constipation Drugs Market by Country, 2018-2030
- 14.1.3 Europe Opioid Induced Constipation Drugs Market Attractiveness Analysis by Country
- 14.2 Europe Opioid Induced Constipation Drugs Market Size (2018-2030)
- 14.2.1 Europe Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.2.1.1 Lubiprostone
- 14.2.1.1.1 Europe Lubiprostone Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.2 Methyl Naltrexone Bromide
- 14.2.1.2.1 Europe Methyl Naltrexone Bromide Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.3 Naldemedine
- 14.2.1.3.1 Europe Naldemedine Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.4 Alvimopan
- 14.2.1.4.1 Europe Alvimopan Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.5 Chloride Channel-2 Activators
- 14.2.1.5.1 Europe Chloride Channel-2 Activators Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.6 Mu-opioid Receptor Antagonists
- 14.2.1.6.1 Europe Mu-opioid Receptor Antagonists Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.7 Other
- 14.2.1.7.1 Europe Other Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.1 Lubiprostone
- 14.2.2 Europe Opioid Induced Constipation Drugs Market (USD Million) by Distribution Channel (2018-2030)
- 14.2.2.1 Hospital Pharmacies
- 14.2.2.1.1 Europe Hospital Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.2 Drug Store and Retail Pharmacies
- 14.2.2.2.1 Europe Drug Store and Retail Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.3 Online Pharmacies
- 14.2.2.3.1 Europe Online Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.1 Hospital Pharmacies
- 14.2.3 Europe Opioid Induced Constipation Drugs Market (USD Million) by Prescription Type (2018-2030)
- 14.2.3.1 Prescribed Drugs
- 14.2.3.1.1 Europe Prescribed Drugs Market Share and Revenue (USD Million) for 2018-2030
- 14.2.3.2 Over The Counter Drugs
- 14.2.3.2.1 Europe Over The Counter Drugs Market Share and Revenue (USD Million) for 2018-2030
- 14.2.3.1 Prescribed Drugs
- 14.2.1 Europe Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.1 Asia Pacific
- 15.1.1 Asia Pacific Opioid Induced Constipation Drugs Market Trends and Analysis
- 15.1.2 Asia Pacific Opioid Induced Constipation Drugs Market by Country, 2018-2030
- 15.1.3 Asia Pacific Opioid Induced Constipation Drugs Market Attractiveness Analysis by Country
- 15.2 Asia Pacific Opioid Induced Constipation Drugs Market Size (2018-2030)
- 15.2.1 Asia Pacific Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.2.1.1 Lubiprostone
- 15.2.1.1.1 Asia Pacific Lubiprostone Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.2 Methyl Naltrexone Bromide
- 15.2.1.2.1 Asia Pacific Methyl Naltrexone Bromide Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.3 Naldemedine
- 15.2.1.3.1 Asia Pacific Naldemedine Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.4 Alvimopan
- 15.2.1.4.1 Asia Pacific Alvimopan Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.5 Chloride Channel-2 Activators
- 15.2.1.5.1 Asia Pacific Chloride Channel-2 Activators Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.6 Mu-opioid Receptor Antagonists
- 15.2.1.6.1 Asia Pacific Mu-opioid Receptor Antagonists Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.7 Other
- 15.2.1.7.1 Asia Pacific Other Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.1 Lubiprostone
- 15.2.2 Asia Pacific Opioid Induced Constipation Drugs Market (USD Million) by Distribution Channel (2018-2030)
- 15.2.2.1 Hospital Pharmacies
- 15.2.2.1.1 Asia Pacific Hospital Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.2 Drug Store and Retail Pharmacies
- 15.2.2.2.1 Asia Pacific Drug Store and Retail Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.3 Online Pharmacies
- 15.2.2.3.1 Asia Pacific Online Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.1 Hospital Pharmacies
- 15.2.3 Asia Pacific Opioid Induced Constipation Drugs Market (USD Million) by Prescription Type (2018-2030)
- 15.2.3.1 Prescribed Drugs
- 15.2.3.1.1 Asia Pacific Prescribed Drugs Market Share and Revenue (USD Million) for 2018-2030
- 15.2.3.2 Over The Counter Drugs
- 15.2.3.2.1 Asia Pacific Over The Counter Drugs Market Share and Revenue (USD Million) for 2018-2030
- 15.2.3.1 Prescribed Drugs
- 15.2.1 Asia Pacific Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.1 Latin America
- 16.1.1 Latin America Opioid Induced Constipation Drugs Market Trends and Analysis
- 16.1.2 Latin America Opioid Induced Constipation Drugs Market by Country, 2018-2030
- 16.1.3 Latin America Opioid Induced Constipation Drugs Market Attractiveness Analysis by Country
- 16.2 Latin America Opioid Induced Constipation Drugs Market Size (2018-2030)
- 16.2.1 Latin America Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.2.1.1 Lubiprostone
- 16.2.1.1.1 Latin America Lubiprostone Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.2 Methyl Naltrexone Bromide
- 16.2.1.2.1 Latin America Methyl Naltrexone Bromide Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.3 Naldemedine
- 16.2.1.3.1 Latin America Naldemedine Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.4 Alvimopan
- 16.2.1.4.1 Latin America Alvimopan Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.5 Chloride Channel-2 Activators
- 16.2.1.5.1 Latin America Chloride Channel-2 Activators Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.6 Mu-opioid Receptor Antagonists
- 16.2.1.6.1 Latin America Mu-opioid Receptor Antagonists Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.7 Other
- 16.2.1.7.1 Latin America Other Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.1 Lubiprostone
- 16.2.2 Latin America Opioid Induced Constipation Drugs Market (USD Million) by Distribution Channel (2018-2030)
- 16.2.2.1 Hospital Pharmacies
- 16.2.2.1.1 Latin America Hospital Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.2 Drug Store and Retail Pharmacies
- 16.2.2.2.1 Latin America Drug Store and Retail Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.3 Online Pharmacies
- 16.2.2.3.1 Latin America Online Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.1 Hospital Pharmacies
- 16.2.3 Latin America Opioid Induced Constipation Drugs Market (USD Million) by Prescription Type (2018-2030)
- 16.2.3.1 Prescribed Drugs
- 16.2.3.1.1 Latin America Prescribed Drugs Market Share and Revenue (USD Million) for 2018-2030
- 16.2.3.2 Over The Counter Drugs
- 16.2.3.2.1 Latin America Over The Counter Drugs Market Share and Revenue (USD Million) for 2018-2030
- 16.2.3.1 Prescribed Drugs
- 16.2.1 Latin America Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.1 Middle East and Africa
- 17.1.1 Middle East and Africa Opioid Induced Constipation Drugs Market Trends and Analysis
- 17.1.2 Middle East and Africa Opioid Induced Constipation Drugs Market by Country, 2018-2030
- 17.1.3 Middle East and Africa Opioid Induced Constipation Drugs Market Attractiveness Analysis by Country
- 17.2 Middle East and Africa Opioid Induced Constipation Drugs Market Size (2018-2030)
- 17.2.1 Middle East and Africa Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.2.1.1 Lubiprostone
- 17.2.1.1.1 Middle East and Africa Lubiprostone Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.2 Methyl Naltrexone Bromide
- 17.2.1.2.1 Middle East and Africa Methyl Naltrexone Bromide Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.3 Naldemedine
- 17.2.1.3.1 Middle East and Africa Naldemedine Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.4 Alvimopan
- 17.2.1.4.1 Middle East and Africa Alvimopan Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.5 Chloride Channel-2 Activators
- 17.2.1.5.1 Middle East and Africa Chloride Channel-2 Activators Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.6 Mu-opioid Receptor Antagonists
- 17.2.1.6.1 Middle East and Africa Mu-opioid Receptor Antagonists Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.7 Other
- 17.2.1.7.1 Middle East and Africa Other Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.1 Lubiprostone
- 17.2.2 Middle East and Africa Opioid Induced Constipation Drugs Market (USD Million) by Distribution Channel (2018-2030)
- 17.2.2.1 Hospital Pharmacies
- 17.2.2.1.1 Middle East and Africa Hospital Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.2 Drug Store and Retail Pharmacies
- 17.2.2.2.1 Middle East and Africa Drug Store and Retail Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.3 Online Pharmacies
- 17.2.2.3.1 Middle East and Africa Online Pharmacies Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.1 Hospital Pharmacies
- 17.2.3 Middle East and Africa Opioid Induced Constipation Drugs Market (USD Million) by Prescription Type (2018-2030)
- 17.2.3.1 Prescribed Drugs
- 17.2.3.1.1 Middle East and Africa Prescribed Drugs Market Share and Revenue (USD Million) for 2018-2030
- 17.2.3.2 Over The Counter Drugs
- 17.2.3.2.1 Middle East and Africa Over The Counter Drugs Market Share and Revenue (USD Million) for 2018-2030
- 17.2.3.1 Prescribed Drugs
- 17.2.1 Middle East and Africa Opioid Induced Constipation Drugs Market (USD Million) by Drug Type (2018-2030)
- 18.1 Key Takeaways
- 18.2 Analyst Point of View
- 18.3 Assumptions
| Segmentation Level Customization | |
| Global level Data Customization | |
| Region level Data Customization | |
| Country level Data Customization | |
| Company Level | |
| Additional Data Analysis | |
| Additional Qualitative Data | |
| Additional Quantitative Data | |
| Service Level Customization | Report Format Alteration |
We have various report editions of Opioid Induced Constipation Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Opioid Induced Constipation Drugs Market Analysis
Global Opioid Induced Constipation Drugs Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Opioid Induced Constipation Drugs Industry growth. Opioid Induced Constipation Drugs market has been segmented with the help of its Drug Type, Distribution Channel Prescription Type, and others. Opioid Induced Constipation Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Report scope is customizable as we have a huge database of Opioid Induced Constipation Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
| Major Drug Type Analysed |
|
| Major Distribution Channel Analysed |
|
| Major Prescription Type Analysed |
|
| Top Manufacturers Disclosed |
|
| Global, Regional and Country Analysis |
|
| Key Qualitative Information Covered |
|
By Type, the Mu-opioid Receptor Antagonists segment has the largest revenue share of Opioid Induced Constipation Drugs Market!
Based on drug type, the Mu-opioid receptor antagonists segment has the largest revenue share in the opioid-induced constipation drugs market. This is due to the increasing number of launches of products by the major players for the treatment of opioid-induced constipation and evaluating research activities for the efficacy and safety of agents. This is projected to drive the growth of this segment.
- Lubiprostone
- Methyl Naltrexone Bromide
- Naldemedine
- Alvimopan
- Chloride Channel-2 Activators
- Mu-opioid Receptor Antagonists
- Other
Opioid Induced Constipation Drugs Market Share (%) by Drug Type in 2018-2030
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Opioid Induced Constipation Drugs Industry. Request a Free Sample PDF!
By Distributional Channel, the Drug Stores and Retail Pharmacies segment has the largest market share of Opioid Induced Constipation Drugs Market!
Based on distribution channels, the drug store and retail pharmacies segment has the largest market share in the opioid-induced constipation drugs market. This is attributed to the increasing preference of people for retail pharmacies and retail pharmacies guide patients about the use and medication during the treatment.
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Pharmacies
Opioid Induced Constipation Drugs Market Share (%) by Distribution Channel in 2018-2030
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Opioid Induced Constipation Drugs market report 2023 Edition by contacting our team.
Opioid Induced Constipation Drugs Prescription Type Segment Analysis
Based on the prescription type, the prescribed drugs segment has the major revenue share in the opioid-induced constipation drugs market. This is owing to the increasing availability of key drugs and the number of key players manufacturing formulations likely to drive the growth of this segment.
- Prescribed Drugs
- Over The Counter Drugs
The North America Opioid Induced Constipation Drugs Market dominates the overall market:
North America has the largest revenue share in the opioid-induced constipation drugs market. This is owing to the increasing occurrence of opioid-induced constipation cases and healthcare infrastructure advancement and the number of major players offering novel therapeutics in the region. This is anticipated to drive the growth of the opioid-induced constipation drugs market in the region.
Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Opioid Induced Constipation Drugs Market Share (%) by Region (2018-2030)
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
Opioid-Induced Constipation Drugs Industry News:
In February 2021, RedHill Biopharma announced the agreement with Cosmo Pharmaceuticals for the manufacturing of Movantik and RHB-204 designed to treat opioid-induced constipation (OIC) in adult patients.
Top Companies Market Share in Opioid Induced Constipation Drugs Industry: (In no particular order of Rank)
- Ironwood Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Pfizer
- Progenics Pharmaceuticals Inc
- Shionogi Co. Ltd
- Allergan Plc
- Nektar Therapeutics
- Purdue Pharma
- S.L.A. Pharma AG
- Mundipharma International Limited
- Ono Pharmaceutical Co. Ltd
- Takeda Pharmaceutical Company Limited
- Theravance Biopharma Inc
- Valeant Pharmaceuticals International
- Cosmo Pharmaceuticals SA
- Daewoong Pharmaceutical
- C.B. Fleet Company
- Sucampo Pharmaceuticals
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Opioid Induced Constipation Drugs Market is witnessing significant growth in the near future.
In 2022, the Lubiprostone segment accounted for noticeable share of global Opioid Induced Constipation Drugs Market and is projected to experience significant growth in the near future.
The Hospital Pharmacies segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Ironwood Pharmaceuticals Inc, Pfizer and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Author's Detail
Surabhi Bhaiyya, LinkedIn
Senior Research Analyst at Cognitive Market Research
Surabhi Bhaiyya is an experienced market researcher focused on the Pharma & Healthcare industry. With over 7+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry. To get in touch and access the above report book an apointment at https://calendly.com/speak-to-analyst.
Key Questions Answered By Opioid Induced Constipation Drugs Market Report 2023
| Why Lubiprostone have a significant impact on Opioid Induced Constipation Drugs market? |
| What are the key factors affecting the Lubiprostone and Methyl Naltrexone Bromide of Opioid Induced Constipation Drugs Market? |
| What is the CAGR/Growth Rate of Hospital Pharmacies during the forecast period? |
| By type, which segment accounted for largest share of the global Opioid Induced Constipation Drugs Market? |
| Which region is expected to dominate the global Opioid Induced Constipation Drugs Market within the forecast period? |
Frequently Asked Questions
Opioid Induced Constipation Drugs market size and its growth rate has been provided in the report. The historical period included in the report is from 2018 to 2022, whereas, the report provides forecast data for the years 2023 to 2030. This will help you to in terms of global market share, regional market share, country level market share to understand how the market has been performing in the past and how it is going to perform in the following years. Correspondingly, historical and forecast analysis comprises sales and revenue data of the global Opioid Induced Constipation Drugs market. Market size for UK, Europe, North America, Asia Pacific, Middle East & Africa is also included in the report.
The major factors affecting the Opioid Induced Constipation Drugs market in a positive, as well as negative perspective, have been provided with detailed analysis in the report. This segment has encompassed drivers, opportunities, and challenges faced by the industry. This will help you to understand the major factors impacting Opioid Induced Constipation Drugs market trends and develop your business strategy accordingly.
Major manufacturers or list of Opioid Induced Constipation Drugs manufacturers 2023 involved in the market have been profiled in the report along with their business strategies, recent developments, SWOT analysis, business overview, and market Trend from the year 2018-2022. Opioid Induced Constipation Drugs Companies such as Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Pfizer, Progenics Pharmaceuticals Inc, Shionogi Co. Ltd, Allergan Plc, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma AG, Mundipharma International Limited, Ono Pharmaceutical Co. Ltd, Takeda Pharmaceutical Company Limited, Theravance Biopharma Inc, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals are part of the final deliverable document along with the same we can provide data for 2nd, 3rd, start-up level companies data and strategies as well . This will help you to understand the competitive analysis of the market and how other players are performing in the market. This detailed competitive analysis will help you to strategize your business accordingly and will keep you one step ahead. A quantitative and qualitative analysis of the main players in the Opioid Induced Constipation Drugs market is introduced, from the perspective of sales, revenue and price.
Under Opioid Induced Constipation Drugs market segments analysis Drug Type, Distribution Channel Prescription Type. It provides detailed insights on each type and application. Further, it provides which sub-segment is dominating the Opioid Induced Constipation Drugs market along with its reason. Additionally, the Opioid Induced Constipation Drugs market report will help you to analyze which sub-segment is fastest-growing during the forecast period.
After the analysis of the complete market, the report has provided how the COVID-19 pandemic has affected the market. All the parameters have covered the overall impact of COVID -19 on the market value, market trend & growth of the market, and how the major players in the particular market are adopting these changes. This will help you to understand the overall optimistic, pessimistic, and neutral effects of the coronavirus pandemic on the Opioid Induced Constipation Drugs market.
The Opioid Induced Constipation Drugs market has been analyzed thoroughly and has estimated the parameters which have affected the market in the historical period as well as how the market is going to perform in the following years. This will provide a complete market scenario and help you to strategize your next move accordingly to the Opioid Induced Constipation Drugs market Share.
The report gives an exhaustive investigation of the Opioid Induced Constipation Drugs market at country & regional levels, and provides an analysis of the industry trends in each of the regions, from sales, revenue, and consumption. It will help you to understand which region is dominating the market and is expected to grow significantly in the following years. The regional analysis will help you in strategizing the expansion of business.
Opioid Induced Constipation Drugs market report has provided PESTEL and Porter analysis to provide insightful information regarding the market scenario. It also provides market attractiveness analysis with an acknowledgment of various factors within the market, including growth rate and market size, as well as outside factors such as access to raw materials, competition, and industry capacity.
The sample report for the Opioid Induced Constipation Drugs Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.
Related Reports
- Measures to Explore Untapped Market
- Understanding Market Dynamics
- Understanding Changing Economics
- Competitors Market Share
- Global/Region/Country Level Analysis
- Identify Upcoming End Use Industries
- Global Price Trend Analysis
- Value Chain Analysis
- Customer Sentiment/Need Analysis
- Identification of Key Growth Segments
- Industry Upstream and Downstream Analysis
- Raw Material Sourcing and Cost Analysis
- Identify Key Customers Across Globe
- Concept Development and Market Testing
- Merger-Acquisition Strategy
- The research study and report are been made exclusively for an institution or person who is strategizing to build a business or strategically wants to expand certain portfolio.
- This report will help in analyzing complete market scenario across the globe who wish to expand their current business or is willing to invest in some profitable sector.
- This report will prove beneficial for person or an organization who wish to be updated regarding their business environment, consumers’ behaviour, and their requirements. The environment is constantly changing, and in such scenario, this report will help in understanding market parameters through 360-degree view.
- The report is thus ideal for KOL, CEO's, CFO's, directors, and others. It is also helpful to senior executives, business development managers, marketing managers, and consultants. Furthermore, government bodies, agencies and other kind of organizations can also leverage our report to understand market.
- Our objective for the Opioid Induced Constipation Drugs market is to help in making imperative business decisions, securing investments, determining new business opportunities in the market. Further, the report helps to analyze overall marketing needs of customers, and avoid business failures.
- To know the potential market size and growth rate before launching a new product line. The report in a way helps in designing R&D budget wisely by estimating maximum total profit.
- To identify the Opioid Induced Constipation Drugs market dynamics, industrial insights, and economic progression for critical information about the market conditions and specific business landscape.
- To assess the overall competitive landscape of a particular business sector and to provide complete analysis in regards with various external factors impacting the market growth.
- To create a strong foundation for building a strategy and foster insight into market conditions so that market players can make better business decisions. Besides, we aim to provide a complete portfolio of the major players involved the market.
- To define the scope which will further help in creating new products that will surpass the gap between current offerings and customers’ needs.
- To help in revealing significant clues concerning buying habits, regional culture, lifestyle, and population density that plays an integral role in shaping market behavior.
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market.
- Competitors Analysis: We provide data from the supplier side covering key details such as market share split among 1st tier, 2nd tier, and 3rd tier, Emerging Players, and Start-Ups. (whereas most of our competitors published data for top-tier companies)
- We provide market revenue share not only for Public listed companies but also the privately listed companies.
- Country Analysis: The Country level market split analysis is part of the report hence the data granularity is provided.
- We have been closely working with the Top 500 Fortune businesses, our clientele spanning 20+ industries. Our clientele is a mix of investors, manufacturers, end-users, distributors, etc. With our data subscription model (Athenaeum) 70% of clients have already subscribed/purchased reports for multiple years which helped us achieve unbelievable client retention statistics.
- Product + Service: In terms of the product we deliver the report access (PDF+ PPT+ EXCEL+ Cloud+ POWER BI) whereas in terms of service; we provide data support where a dedicated research analyst will be assigned and add-on benefits. (Whereas most of our competitors believe only in delivering the data/report and service and support remain questionable.)
- Credibility and Data Accuracy: We deliver accuracy close to 90-95% with the help of our in-house research team, freelancer, and industry expert network, sources present worldwide. This Data is backed up by strong What are our clients saying about our services.
Read more
